Latest A3P Biomedical News & Updates

See the latest news and media coverage for A3P. We track all announcements, press releases, and industry mentions in real time, all in one place.

A3P Biomedical (A3P)

Developer of blood-based prostate cancer diagnostic tests

a3p.com

Headquarters: Stockholm, Sweden
Founded year: 2018
Company type: Private company
Number of employees: 40–50

Last updated Today

Latest news about A3P Biomedical (A3P)

In short: A3P updated its leadership and secured key clinical validations for its Stockholm3 prostate cancer test across global markets.

Company announcements

March 24 A3P

A3P elects O’Connell Chairman and Steinberg CEO

O’Connell brings decades of life sciences experience. Steinberg, co-founder, leads operations and strategy. Transition focuses on global expansion.

March 19 A3P

A3P Biomedical highlights Stockholm3 study as Editor’s Choice

The landmark STHLM3 study in European Urology shows Stockholm3 detects aggressive prostate cancers missed by PSA. CEO Martin Steinberg welcomes the recognition.

March 16 A3P

A3P announces Stockholm3 study wins Best Oncology Abstract at EAU26

The independent study shows Stockholm3 reduces MRI and biopsy needs in Sweden's prostate cancer screening while detecting significant cases.

4 November 2025 A3P

A3P announces Stockholm3 detects aggressive prostate cancers missed by PSA

Nine-year study shows men with positive Stockholm3 and PSA 1.5-3 ng/ml have 9x higher recurrence risk. Published in European Urology.

Media coverage

March 25 Life Science Sweden

A3P changes in the management - medtech veteran takes over the gavel

The diagnostics company A3P Biomedical has appointed the co-founder and former chairman of the board Martin Steinberg as CEO of the company. New chairman of the board is Christopher O´Connell.

4 November 2025 Placera.se

A3P Biomedical: Stockholm3 screening detects aggressive and potentially deadly prostate cancer that is missed by PSA at current threshold values

A3P Biomedical: Stockholm3 screening detects aggressive and potentially deadly prostate cancer that is missed by PSA at current threshold values.

5 March 2025 Affärsvärlden

The pharmaceutical veteran Thomas Eldered is a major shareholder and chairman of the investment company Flerie. Photo: Tobias Ohls. This is evident from a press release. A3P Biomedical has developed Stockholm3, a blood-based..

The pharmaceutical veteran Thomas Eldered is a major shareholder and chairman of the investment company Flerie. Photo: Tobias Ohls. This is evident from a press release. A3P Biomedical has developed Stockholm3, a blood-based...

13 August 2021 PR Newswire

A3P Biomedical AB: Fast track publication of the STHLM3 MRI trial in The Lancet Oncology

STOCKHOLM, Aug. 13, 2021 /PRNewswire/ -- A3P Biomedical AB today announced that the publication of the STHLM3 MRI trial including 12,750 men has been fast...

Never miss news about A3P

Track A3P and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.